Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT07107646
Starting soon Not applicable

Exploring Perceptual Learning in Blurred Gabor Discrimination for Low-Myopic Children

NCT07107646 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-14

Condition(s) studied

MyopiaVisual RehabilitationPerceptual Learning

Investigational drug(s) / intervention(s)

vision training system, VTS

vision training system, VTS: Participants in this group will receive individualized visual perceptual learning using the Vision Training System (VTS). The training involves blurred Gabor stimuli presented via a computer-based application. Each participant will complete approximately 20 training sessions over 3 months, with each session lasting 15 to 30 minutes, conducted twice per week. The program is designed to enhance uncorrected visual acuity, contrast sensitivity, and other visual functions by engaging neural mechanisms related to perceptual learning. Training progression is adaptive based on individual performance. The VTS software was developed in collaboration with Bar Ilan University.

Study summary

This exploratory study investigates whether perceptual learning using blurred Gabor stimuli can improve uncorrected distance visual acuity in children aged 6-10 years with low myopia. Participants will be randomly assigned to a training group or control group. The training group will undergo individualized visual perceptual learning through a digital Vision Training System (VTS) for approximately 3 months. The study will also evaluate changes in refraction, contrast sensitivity, visual crowding, Chinese reading acuity with eye movements, and sweep visual evoked potentials (sVEPs).

Eligibility

Sex
ALL
Min age
6 Years
Max age
10 Years
Healthy volunteers
No
Experimental and Control Group Inclusion Criteria: 1. Children aged between 6 to 10 years. 2. Best corrected distance visual acuity of 6/6 or 0.00 logMAR. 3. Diagnosed with low myopia after a comprehensive ophthalmologic examination, with a spherical equivalent refractive error ranging from -0.50 to -1.25 diopters, including up to -0.75 diopters of astigmatism. 4. Not currently undergoing any of the four standard myopia control treatments for children: 1. Atropine (mydriatic agent) 2. Orthokeratology 3. Peripheral defocus soft contact lenses 4. Peripheral defocus spectacle lenses (frame glasses) 5. Willing and able to provide informed consent, and able to comply with study procedures and assessments. Exclusion Criteria: Participants will be excluded if they have any of the following ophthalmologic conditions: 1. Strabismus 2. Binocular vision problems 3. Ocular diseases 4. History of ocular surgery (excluding refractive surgery)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Occupational Therapy, College of Medicine, National Taiwan University Taipei Taiwan

More National Taiwan University Hospital trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07107646 on ClinicalTrials.gov ↗ ← All trials in Taiwan